MHRA sets out Pathways trial review; professor recused
Here’s the short version: the UK’s medicines regulator, the MHRA, says participant safety leads every decision on the Pathways clinical trial. In a statement on GOV.UK, the agency confirmed it is actively reviewing the study, is in regular scientific discussions with the sponsor, and will keep meeting King's College London about next steps.
If you’re new to this world, think of the MHRA as the referee for research involving medicines and medical devices. It authorises trials to start, sets conditions, and can ask for changes or pauses if new information suggests a risk to people taking part.
The MHRA also said complex trials are kept under continuous review. Many modern studies use adaptive designs or work across multiple groups; that makes ongoing checks vital so the trial stays ethical, scientifically sound and safe while results come in.
‘Active scientific dialogue’ might sound technical, but it’s straightforward. Regulators meet sponsors and investigators to test the evidence, ask for additional analyses, and agree any changes to protocols. The MHRA says those conversations with King's College London will continue constructively.
The agency added one clear step on governance: Professor Jacob George has been recused from any further involvement in the Pathways trial. This follows the identification of social media posts made before his appointment. The MHRA describes the move as precautionary.
What does recused mean in practice? It means a person steps back from decisions or access to information on a case where there could be a perceived conflict of interest. It does not decide the rights or wrongs of past comments; it protects trust while the work carries on.
Why does this matter for participants? Safety oversight in the UK is layered. Investigators monitor day to day. Sponsors check quality and data. Ethics committees review the study’s design and consent. The MHRA looks across the whole picture and can intervene at any time.
For students studying clinical research, this is a live example of due process. You can map the steps: ongoing monitoring, open dialogue between sponsor and regulator, and the use of recusal to prevent real or perceived bias. Each step aims to protect participants and the integrity of results.
If you’re an educator, this is a useful moment to discuss digital footprints and professional roles. Comments posted online-even years earlier-can create the appearance of bias. Organisations often respond with temporary measures, like recusal, to keep decision-making clean.
What happens next? According to the MHRA’s statement, expert teams will keep meeting and make evidence-based decisions as information develops. That could include confirming the current plan, requesting amendments, or, if needed, pausing parts of a study. The principle stays the same: people’s safety comes first.